Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy
Introduction: Dapagliflozin exerts renoprotective effects in patients with IgA nephropathy (IgAN). However, the association between the pretreatment estimated glomerular filtration rate (eGFR) slope and posttreatment outcomes in patients with slowly progressing IgAN with optimal standard care is unc...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024925002670 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473082503200768 |
|---|---|
| author | Hiroyuki Ueda Nobuo Tsuboi Kei Matsumoto Shohei Fukunaga Akihiro Shimizu Masahiro Okabe Shinya Yokote Takaya Sasaki Takashi Yokoo |
| author_facet | Hiroyuki Ueda Nobuo Tsuboi Kei Matsumoto Shohei Fukunaga Akihiro Shimizu Masahiro Okabe Shinya Yokote Takaya Sasaki Takashi Yokoo |
| author_sort | Hiroyuki Ueda |
| collection | DOAJ |
| description | Introduction: Dapagliflozin exerts renoprotective effects in patients with IgA nephropathy (IgAN). However, the association between the pretreatment estimated glomerular filtration rate (eGFR) slope and posttreatment outcomes in patients with slowly progressing IgAN with optimal standard care is unclear. Methods: This study included patients with biopsy-confirmed IgAN who were prescribed dapagliflozin during outpatient visits (August 2021–March 2022). Longitudinal eGFR and proteinuria data were analyzed 2 to 3 years before and after treatment. The eGFR slope and time-averaged urinary protein-to-creatinine ratio (UPCR) were compared between the pretreatment period and the posttreatment chronic phase (≥ 90 days). Multivariable regression analysis was performed to examine the association between the pretreatment eGFR slope and posttreatment changes in the slope. Results: A total of 84 patients (median age: 55.5 years; 38% female; median eGFR: 40.0 ml/min per 1.73 m2; median follow-up: 10.4 years at dapagliflozin initiation) were analyzed. The eGFR slope improved significantly from −1.92 to −0.69 ml/min per 1.73 m2/yr, whereas time-averaged UPCR remained unchanged during observation periods of 1161 and 1050 days pretreatment and posttreatment, respectively. Patients with a steeper pretreatment eGFR decline tended to show greater posttreatment improvement. Multivariable analysis showed that the pretreatment eGFR slope was independently associated with the posttreatment eGFR slope after adjusting for confounders, including pretreatment UPCR. Conclusion: Dapagliflozin was associated with a slower eGFR decline in patients with IgAN, particularly those with a steeper pretreatment eGFR slope, suggesting that pretreatment eGFR slope may help guide individualized therapy. |
| format | Article |
| id | doaj-art-4999a1406cf54604b5e02c766d4602b0 |
| institution | Kabale University |
| issn | 2468-0249 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-4999a1406cf54604b5e02c766d4602b02025-08-20T03:24:16ZengElsevierKidney International Reports2468-02492025-07-011072405241310.1016/j.ekir.2025.04.042Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA NephropathyHiroyuki Ueda0Nobuo Tsuboi1Kei Matsumoto2Shohei Fukunaga3Akihiro Shimizu4Masahiro Okabe5Shinya Yokote6Takaya Sasaki7Takashi Yokoo8Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Correspondence: Hiroyuki Ueda, Division of Nephrology and Hypertension, The Jikei University School of Medicine, 3-19-18, Nishi-shinbashi, Minato-ku, Tokyo 105-8471, Japan.Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanIntroduction: Dapagliflozin exerts renoprotective effects in patients with IgA nephropathy (IgAN). However, the association between the pretreatment estimated glomerular filtration rate (eGFR) slope and posttreatment outcomes in patients with slowly progressing IgAN with optimal standard care is unclear. Methods: This study included patients with biopsy-confirmed IgAN who were prescribed dapagliflozin during outpatient visits (August 2021–March 2022). Longitudinal eGFR and proteinuria data were analyzed 2 to 3 years before and after treatment. The eGFR slope and time-averaged urinary protein-to-creatinine ratio (UPCR) were compared between the pretreatment period and the posttreatment chronic phase (≥ 90 days). Multivariable regression analysis was performed to examine the association between the pretreatment eGFR slope and posttreatment changes in the slope. Results: A total of 84 patients (median age: 55.5 years; 38% female; median eGFR: 40.0 ml/min per 1.73 m2; median follow-up: 10.4 years at dapagliflozin initiation) were analyzed. The eGFR slope improved significantly from −1.92 to −0.69 ml/min per 1.73 m2/yr, whereas time-averaged UPCR remained unchanged during observation periods of 1161 and 1050 days pretreatment and posttreatment, respectively. Patients with a steeper pretreatment eGFR decline tended to show greater posttreatment improvement. Multivariable analysis showed that the pretreatment eGFR slope was independently associated with the posttreatment eGFR slope after adjusting for confounders, including pretreatment UPCR. Conclusion: Dapagliflozin was associated with a slower eGFR decline in patients with IgAN, particularly those with a steeper pretreatment eGFR slope, suggesting that pretreatment eGFR slope may help guide individualized therapy.http://www.sciencedirect.com/science/article/pii/S2468024925002670dapagliflozineGFR slopeIgA nephropathyproteinuria |
| spellingShingle | Hiroyuki Ueda Nobuo Tsuboi Kei Matsumoto Shohei Fukunaga Akihiro Shimizu Masahiro Okabe Shinya Yokote Takaya Sasaki Takashi Yokoo Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy Kidney International Reports dapagliflozin eGFR slope IgA nephropathy proteinuria |
| title | Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy |
| title_full | Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy |
| title_fullStr | Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy |
| title_full_unstemmed | Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy |
| title_short | Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy |
| title_sort | pretreatment gfr slopes predict dapagliflozin response in iga nephropathy |
| topic | dapagliflozin eGFR slope IgA nephropathy proteinuria |
| url | http://www.sciencedirect.com/science/article/pii/S2468024925002670 |
| work_keys_str_mv | AT hiroyukiueda pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy AT nobuotsuboi pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy AT keimatsumoto pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy AT shoheifukunaga pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy AT akihiroshimizu pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy AT masahirookabe pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy AT shinyayokote pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy AT takayasasaki pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy AT takashiyokoo pretreatmentgfrslopespredictdapagliflozinresponseiniganephropathy |